Read ALCMI's Press Releases

September 9, 2024

Viz.ai and ALCMI Partner to Unite AI and Lung Cancer Research Communities

New partnership brings together AI experts and lung cancer researchers to improve early disease detection

April 17, 2024

GO2 for Lung Cancer, Dana-Farber Cancer Institute, and Addario Lung Cancer Medical Institute Announce Expansion of Landmark Patient Research on Underlying Causes of Inherited Risk of Lung Cancer

GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), announced a major expansion of landmark research studying genetic risk for developing lung cancer.

November 30, 2022

New Study to Address Cancer Treatment Resistance for People Who Are KRAS Positive

The Addario Lung Cancer Medical Institute (ALCMI) has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and other cancer types.

May 26, 2021

First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

February 23, 2021

New Study Seeks Origins of Young Lung Cancer

January 11, 2019

Remote Participation Enables Patients with ALK-Positive Lung Cancer from Across the Country to Participate in New Study of Treatment Resistance

November 14, 2018

Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

August 29, 2018

The Bonnie J. Addario Lung Cancer Foundation Joins Forces with Patient Advocate Group to Advance Care for People with EGFR-Positive Lung Cancer

June 1, 2018

Addario Lung Cancer Medical Institute Collaborate with Washington University on ctDNA Analysis in Early Stage Lung Cancer Study

May 31, 2018

Press Releases